Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cellebrite DI (CLBT) Change in Account Payables: 2019-2024

Historic Change in Account Payables for Cellebrite DI (CLBT) over the last 6 years, with Dec 2024 value amounting to $2.8 million.

  • Cellebrite DI's Change in Account Payables rose 66.20% to $713,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $3.4 million, marking a year-over-year increase of 506.42%. This contributed to the annual value of $2.8 million for FY2024, which is 25.36% down from last year.
  • Per Cellebrite DI's latest filing, its Change in Account Payables stood at $2.8 million for FY2024, which was down 25.36% from $3.7 million recorded in FY2023.
  • In the past 5 years, Cellebrite DI's Change in Account Payables registered a high of $4.2 million during FY2021, and its lowest value of -$5.5 million during FY2022.
  • Moreover, its 3-year median value for Change in Account Payables was $2.8 million (2024), whereas its average is $325,000.
  • Its Change in Account Payables has fluctuated over the past 5 years, first tumbled by 247.13% in 2020, then spiked by 395.81% in 2021.
  • Over the past 5 years, Cellebrite DI's Change in Account Payables (Yearly) stood at -$1.4 million in 2020, then spiked by 395.81% to $4.2 million in 2021, then tumbled by 229.06% to -$5.5 million in 2022, then soared by 167.46% to $3.7 million in 2023, then decreased by 25.36% to $2.8 million in 2024.